Abstract: This invention discloses an approach regarding the use of solid-phase microextractions (SPMEs) in the analytical, bioanalytical, combinatorial sciences, and all other applicable areas of measurement science. The approach applies to the analysis of exceedingly small volumes of a liquid specimen (10s-100s of ?L), and how the concepts of negligible depletion (ND) can be used within the context of tradeoff between extractive (reaction) kinetics, extractive capacity, and sample flow rate as a means to obviate the need to deliver accurately a small volume sample for SPME analysis, improving the ease-of-use for a number of different SPME-based measurements including, for example, disease markers in immunoassays for health care.

Abstract: A method for producing a particulate titanium alloy product can include preparing a composite particulate oxide mixture with TiO2 powder and at least one alloying element powder. The composite particulate oxide mixture can be co-reduced using a metallic reducing agent under a hydrogen atmosphere at a reduction temperature for a reduction time sufficient to produce a hydrogenated titanium alloy product. The hydrogenated titanium alloy product can then be heat treated under a hydrogen atmosphere and a heat treating temperature to reduce pore size and specific surface area to form a heat treated hydrogenated titanium product. The heat treated hydrogenated titanium product can be deoxygenated to reduce residual oxygen to less than 0.2 wt % to form a deoxygenated hydrogenated titanium product as a particulate. The deoxygenated hydrogenated titanium product can optionally be dehydrogenated to form the titanium alloy product as a particulate.

Abstract: Methods, kits and mixtures are provided for performing RT-PCR with an RT incubation of no more than one minute and PCR cycles in <20 seconds per cycle.

Abstract: A composite solid electrolyte (100) for lithium batteries can include a solid polymer (110), phyllosilicate nanoparticles (120) distributed in the solid polymer, and a lithium salt (130) distributed in the solid polymer. In one example, the composite solid electrolyte can be used in a solid state lithium battery cell (400) made up of composite solid electrolyte, an anode (420) containing lithium in contact with a first surface of the composite solid electrolyte, and a cathode (430) in contact with a second surface of the composite solid electrolyte.

Abstract: Disclosed herein are compounds and methods for inhibiting Arf6. Pharmaceutical compositions and methods for treating a subject with an inhibitor of Arf6 are also disclosed herein.

Abstract: A nerve repair conduit configured to be secured on first and second portions of a selected nerve. The nerve repair conduit includes a polymeric body having a proximal end, a distal end, an exterior surface and an interior surface defining an interior lumen. In addition, the nerve conduit includes at least one drug reservoir to hold agent(s) that may facilitate nerve regeneration. The drugs diffuse from the drug reservoir(s) into the nerve repair conduit through an outlet (such as a hole or a semipermeable membrane) in proximity to the first and second portions of a selected nerve. The nerve repair conduit may be configured to deliver the agent(s) at a rate having substantially zero-order kinetics and/or at a constant rate over a selected period of time.

Abstract: A variable focus optical device (100) can include first optically transparent membrane (102) and a second membrane (104) that at least partially define a chamber (106) retaining an optically transparent liquid. A transparent piston (110) is attached to the second membrane (104). At least one actuator (112a-c) is operatively coupled to the transparent piston (110) and configured to move to change a focal length of the variable focus optical device (100) via actuation of the transparent piston (110). Three curved bimorph actuators (112a-c) can surround and be coupled to the piston (110) for actuation of the piston (110) to generate a plano-convex or plano-concave lens via the membranes (102, 104). A smart eyeglasses system includes a pair of variable focus optical devices (100), an object distance sensor, a battery, optional eye-tracking camera(s), and a microcontroller, collectively used for purposes of sensing distance of objects and adjusting said focal length via the variable focus optical devices (100).

Abstract: A computer implemented method for measuring T1 in an anatomical region of interest during a dynamic procedure includes acquiring a reference MR image of the anatomical region of interest using a first flip angle. A first set of dynamic MR images of the anatomical region of interest are acquired using a second flip angle. The reference MR image and the first set are used to calculate a reference T1 value for tissue in the anatomical region of interest. During an intervention where the T1 value may change, a second set of dynamic MR images of the anatomical region of interest is acquired using the second flip angle. The reference MR image and the second set are used to calculate an estimated T1 value. The reference T1 value, the estimated T1 value, and the first and second flip angles may then be used to correct the estimated T1 value.

Abstract: A system may assist with checking policy impact in a software-defined infrastructure environment. The system's data analysis may enable it to discover and quantify the impact of policies on software-defined infrastructure objects in the same or different layers.

Abstract: A therapeutic ultrasound breast treatment device (101) is disclosed. The device (101) can include a receptacle (130) to receive a breast of a patient therein. The device (101) can also include an ultrasound transducer assembly disposed proximate the receptacle and oriented to direct a high intensity ultrasound transmission through an opening (168) of the receptacle (130) toward the breast. The device (101) can include a liner (1 60) disposed in the receptacle (130) to contain an ultrasound coupling fluid about the breast. The liner (160) can have an extension portion that extends through the opening (168) to form a seal with the ultrasound transducer assembly to prevent leakage of the ultrasound coupling fluid. A focus location of the ultrasound transmission can be adjustable and the device (101) can include a plurality of RF tracking coils to determine the focus location of the ultrasound transmission to facilitate adjustment of the focus location in an MRI environment.

Abstract: A system may assist with checking policy impact in a software-defined infrastructure environment. It may perform continuous learning of impact using emulations under varying conditions and may take a statistical and machine learning based analysis approach on the data obtained from emulations. The system's data analysis may enable it to discover and quantify the impact of policies on software-defined infrastructure objects in the same or different layers.

Abstract: A multi-site electrode array (100) can include a microneedle array and a set of electrically active sites (115). The microneedle array includes a plurality of microneedles (105) supported on a base substrate (110). The set of electrically active sites (115) can be arranged at and/or near the tip of each microneedle (105), and in many cases along a shaft of the microneedles. Further, at least a portion of the active sites (115) can be independently electrically addressable such that a remaining portion of the active sites (115) are optionally electrically shunted together. In some cases all of the active sites (115) are independently electrically addressable.

Abstract: Disclosed are compositions and methods for expressing and purifying a peptide of interest using a Flagellar Type III secretion system. Disclosed are nucleic acid sequences that contain a FlgM nucleic acid sequence, a cleavage site, and a nucleic acid sequence of interest. Also disclosed are polypeptides that contain FlgM, a cleavage site and a peptide of interest. Methods of producing polypeptides that have FlgM, a cleavage site and a peptide of interest are provided.

Abstract: A method for reducing artifacts in magnetic resonance imaging (MRI) data includes acquiring a k-space dataset of an anatomical subject using a MRI scanner. An iterative compressed sensing reconstruction method is used to generate a reconstructed image based on the k-space dataset. This iterative compressed sensing reconstruction method uses (a) L1-norm based total variation constraints applied the temporal and spatial dimensions of the k-space dataset and (b) a low rank constraint. After the reconstructed image is generated, a deep learning network is used to generate an artifact image depicting motion artifacts present in the reconstructed image. The reconstructed image is subtracted from the artifact image to yield a final image with the motion artifacts removed.

Abstract: A nerve repair conduit configured to be secured on first and second portions of a selected nerve. The nerve repair conduit includes a polymeric body having a proximal end, a distal end, an exterior surface and an interior surface defining an interior lumen. In addition, the nerve conduit includes at least one drug reservoir to hold agent(s) that may, for example, facilitate nerve regeneration. The drugs diffuse from the drug reservoir(s) into the nerve repair conduit through an outlet (e.g., a semipermeable membrane) in proximity to the first and second portions of a selected nerve. The nerve repair conduit may be configured to deliver the agent(s) at a rate having substantially zero-order kinetics and/or at a constant rate over a selected period of time (e.g., at least 1 week).

Abstract: Disclosed herein are compositions and methods for inhibiting respiratory syncytial virus (RSV) entry into a host cell. Also provided herein are methods of identifying a peptide that interacts with the N-trimer of RSV F protein.

Abstract: A therapeutic composition can include an amount of amniotic fluid having a therapeutically effective amount of at least one protein, hyaluronic acid, or both. The therapeutic composition can be substantially free of lanugo, vernix, and cells harvested with the amniotic fluid.

Abstract: Aspects of the present disclosure generally relate to compounds for targeting and healing bone fractures. Some of these compounds include a negatively charged oligopeptide comprising an acidic oligopeptide, a linker, which may be hydrolyzable or may be a substrate for the protease cathepsin K, and at least one molecule that promotes bone healing. In some compounds the molecule that promotes bone healing is an anabolic compound that inhibits GSK3?, in some compounds the molecule that promotes the healing of bone fracture is a pro-inflammatory agent such as PGE1. Other embodiments include methods of treating a bone fracture comprising administering a therapeutic amount of any one of the compounds disclosed herein.

Abstract: A therapeutic delivery device that provides a controlled release of high doses of a therapeutic agent in a local area, sustains the high dose controlled release with a percutaneous port for refilling the device, and is versatile for use with multiple types of therapeutic agents and/or implant systems. A rate determining/controlled release membrane is used to decrease the molecular mobility of the therapeutic compounds thereby controlling the therapeutic release profile. The therapeutic delivery device includes a body defining an internal reservoir for receiving a therapeutic agent and including a first membrane for providing a controlled release of the therapeutic agent to the surgical site, a port in fluid communication with the reservoir, a sleeve configured to encapsulate the body, and a rigid housing configured to support the body and a portion of the sleeve, the rigid housing configured to release the body and the sleeve after the body and the sleeve are anchored position relative to the surgical site.

Abstract: Described herein are fluid complex coacervates that produce solid adhesives in situ. Oppositely charged polyelectrolytes were designed to form fluid adhesive complex coacervates at ionic strengths higher than the ionic strength of the application site, but an insoluble adhesive solid or gel at the application site. When the fluid, high ionic strength adhesive complex coacervates are introduced into the lower ionic strength application site, the fluid complex coacervate is converted to a an adhesive solid or gel as the salt concentration in the complex coacervate equilibrates to the application site salt concentration. In one embodiment, the fluid complex coacervates are designed to solidify in situ at physiological ionic strength and have numerous medical applications. In other aspects, the fluid complex coacervates can be used in aqueous environment for non-medical applications.